NIH-funded research NIH-funded research

Improving vaccines for tuberculosis

Official title: Advancing Vaccine adjuvant Research for Tuberculosis (TB)

Funded at University of Sydney · NIH-11196785 · Data updated 2026-11-12

This study is working on creating better vaccines for tuberculosis, especially for people at higher risk like those with HIV, by testing different ingredients that help boost the vaccine's effectiveness.

Quick facts

Grant typeNIH-funded research
Study typeNIH-funded research
Funding institutionUniversity of Sydney
NIH-funded
Lab location1 site (Sydney, Australia)
Project startSeptember 30, 2022
Project endSeptember 29, 2027
Funding year2024
Award (this year)$800,000
NIH project number75N93022C00041-P00004-9999-2
Project IDNIH-11196785 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals at high risk for tuberculosis, particularly those living with HIV.

Less likely to help

Patients who are not at risk for tuberculosis or those who have already been vaccinated with existing TB vaccines may not benefit from this research.

What this research studies

This research focuses on developing better vaccines for tuberculosis (TB), particularly for individuals at higher risk, such as those living with HIV. The team will compare different vaccine adjuvants—substances that enhance the body's immune response to the vaccine—alongside TB antigens to identify the most effective combinations. Using mouse models, they will evaluate these combinations before testing the best candidates in non-human primates. The ultimate goal is to create vaccines that can prevent TB infection and improve treatment outcomes.

Why it matters

Potential benefit: If successful, this research could lead to more effective vaccines that significantly reduce the incidence of tuberculosis, especially in vulnerable populations.

How similar studies have gone: Previous research has shown promise in enhancing vaccine efficacy through the use of adjuvants, indicating that this approach could lead to significant advancements in TB vaccine development.

Where this research is happening

  • University of Sydney
    Sydney, Australia
    Active

Researchers

  • Principal investigator: Britton, Warwick — University of Sydney
  • Study coordinator: Britton, Warwick

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.